Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04293380 |
| Other study ID # |
suleymanG |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
March 1, 2012 |
| Est. completion date |
September 1, 2016 |
Study information
| Verified date |
December 2020 |
| Source |
Karadeniz Technical University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Down syndrome is the most common genetic disorder in the society that causes mental
retardation. Today, screening tests (combined test, triple screening, ultrasonography and
age) are performed for the diagnosis of down syndrome for all pregnant women. As a result of
screening tests, amniocentesis is performed as a diagnostic test for the group at risk.
Chromosome analysis from amniotic fluid requires a 3-week period for chromosome cultures to
yield results. Several levels of biochemical markers, such as organic acids and pyridoxine
metabolites, have been found to be elevated in the amniotic fluid. The investigators also
plan to investigate ischemia-modified albumin, hepatocyte growth factor level in amniotic
fluid.
Description:
The alpha feto protein level showing liver function is lower in babies with Down syndrome and
this biochemical marker is one of the basic parameters of triple screening.
If these babies have insufficient liver function, then it is likely that there is a decrease
in hepatocyte growth factor in these babies. Free E3 is higher in Down syndrome than normal
pregnant women. Placental hyperfunction, fetal hypofunction (especially based on fetal liver)
is accepted as the hypothetical cause of these two conditions in Down syndrome. In this
study, the investigators think that the real cause of this condition is secondary to fetal
partial hypoxia. For this purpose, the investigators plan to look at the level of IMA in
amniotic fluid. However, Güven et al. In his study, an increased rate of ischemia-modified
albumin was found in the amnion levels of mothers who had high triple screening tests but had
no down syndrome in their babies. In this study, it is aimed to find a change in amniotic
fluid that can help in the diagnosis of down syndrome. In our opinion, in cases of down
syndrome, there will be an increase in IMA in the amniotic fluid secondary to ischemia, which
is more severe than the false triple test positivity.
In our university, chromosome analyzes are made from amnion fluids sent to the Duzen
laboratory. This laboratory hides amniotic fluid of patients with down syndrome (in the
context of an agreement between our university and the laboratory). Within the scope of the
research, amniotic fluids of 20 cases diagnosed with down syndrome in the Department of
Obstetrics and Gynecology of KTU Faculty of Medicine will be obtained from the regulation
laboratory and necessary biochemical evaluations will be performed. As the control group,
amniotic fluids will be provided by 60 patients with normal amniocentesis results. The
demographic factor, obstetric history and gynecological history information of all cases will
be recorded in the questionnaire prepared by one of the researchers. 2 cc amnion sample of
the patients with Down syndrome diagnosis and control group will be taken into the
biochemistry tube and serum IMA and HGF values will be measured in KTU Faculty of Medicine,
Department of Biochemistry. As a result, amnion IMA, HGF values of 20 cases diagnosed with
down syndrome and amnion IMA, HGF values of 60 cases with down syndrome will be entered into
SPSS 10.5 for Windows environment and their mean values will be compared.
According to the results, amniotic fluid IMA values of the study group and control group will
be compared. Thus, it is aimed to eliminate the burden that the chromosome culture will bring
to the national economy with an evaluation made in a routine laboratory in cases diagnosed
with down syndrome.
